SEC Comment Letter for Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554) (MTNB) — Sep 21, 2016
Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554)
Date: Sept. 21, 2016 · CIK: 0001582554 · Accession: 0000000000-16-093846
AI Filing Summary & Sentiment
Letter
Mail Stop 4546 September 21, 2016 Jerome Jabbour President Matinas Biopharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921
Re: Matinas Biopharma Holdings, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 12, 2016 File No. 333 -193455
Dear Mr. Jabbour :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4546 September 21, 2016 Jerome Jabbour President Matinas Biopharma Holdings, Inc. 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 Re: Matinas Biopharma Holdings, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 12, 2016 File No. 333 -193455 Dear Mr. Jabbour : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance